57184-23-3

Basic information

• Product Name: 1-(CYCLOHEXYLMETHYL)PIPERAZINE
• Synonyms: 1-(CYCLOHEXYLMETHYL)PIPERAZINE;Cyclohexylmethylpiperazine;1-(Cyclohexylmethyl)piperazine 97%;1-(Cyclohexylmethyl)piperazine97%;N-(Cyclohexylmethyl)piperazine
• CAS NO: 57184-23-3
• Molecular Formula: C₁₁H₂₂N₂
• Molecular Weight: 182.31
• Product Categories: Amines and Anilines;API intermediates;Building Blocks;Heterocyclic Building Blocks;Piperazines
• Mol File: 57184-23-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 230-231 °C(lit.)
• Flash Point: 190 °F
• Appearance: Colorless/Liquid
• Density: 0.938 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.4950(lit.)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.26±0.10(Predicted)
• CAS DataBase Reference: 1-(CYCLOHEXYLMETHYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(CYCLOHEXYLMETHYL)PIPERAZINE(57184-23-3)
• EPA Substance Registry System: 1-(CYCLOHEXYLMETHYL)PIPERAZINE(57184-23-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: NA 1993 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 57184-23-3(Hazardous Substances Data)

Usage

General Description

1-(Cyclohexylmethyl)piperazine is a chemical compound with the molecular formula C12H24N2. It is a piperazine derivative that is commonly used as an intermediate in the synthesis of various pharmaceuticals, including antihistamines, antipsychotics, and antiviral agents. 1-(CYCLOHEXYLMETHYL)PIPERAZINE is known for its ability to act as a neurotransmitter and plays a role in modulating serotonin and dopamine levels in the central nervous system. It is also used as a reagent in organic synthesis and as a building block for the creation of diverse molecular structures in medicinal chemistry. Additionally, 1-(Cyclohexylmethyl)piperazine has been studied for its potential as a therapeutic agent in the treatment of neurological disorders and mood-related conditions.

Upstream product

• 5625-67-2 2-Ketopiperazine 
• 98-89-5 Cyclohexanecarboxylic acid 
• 2043-61-0 cyclohexanecarbaldehyde 
• 1206676-28-9 tert-butyl 4-(cyclohexylmethyl)piperazine-1-carboxylate 
• 7755-92-2 piperazine-1-carbaldehyde 
• 2550-36-9 Cyclohexylmethyl bromide 
• 412293-89-1 4-Cyclohexylmethyl-piperazine-1-carbaldehyde 

Downstream Products

• 102535-29-5 3-(4-Cyclohexylmethyl-piperazine-1-carbonyl)-4-methoxy-benzenesulfonamide 
• 134346-48-8 1-(cyclohexylmethyl)-4-<4-<(2,3-dihydro-2-oxo-1H-imidazo<4,5-b>quinolin-7-yl)oxy>-1-oxobutyl>-1-piperazine 
• 1218949-66-6 2-[4-(cyclohexylmethyl)piperazin-1-yl]-1-[3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl]ethanone 
• 1254211-04-5 (E)-ethyl 3-(3-(4-(cyclohexylmethyl)piperazine-1-carbonyl)-phenyl)acrylate 
• 1277167-61-9 C₂₁H₂₇ClN₄O 
• 1428245-55-9 C₁₈H₂₇ClN₂O₃ 
• 1584124-77-5 C₁₉H₃₈N₂O 
• 1377239-83-2 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one 

Relevant articles and documents

Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis

8-Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic pathway to BTZs was established. It allows the formation of the thiazinone ring system in one synthetic step and is applicable for preparation of a wide variety of BTZ analogues. The synthetic procedure furthermore facilitates the replacement of the sulphur atom in the thiazinone ring system by oxygen or nitrogen to afford the analogous benzoxazinone and quinazolinone systems. 36 BTZ analogues were prepared and tested in luminescence-based assays for in vitro activity against Mycobacterium tuberculosis (Mtb) using the microdilution broth method and a high-throughput macrophage infection assay.

A practical catalytic reductive amination of carboxylic acids

We report reductive alkylation reactions of amines using carboxylic acids as nominal electrophiles. The two-step reaction exploits the dual reactivity of phenylsilane and involves a silane-mediated amidation followed by a Zn(OAc)2-catalyzed amide reduction. The reaction is applicable to a wide range of amines and carboxylic acids and has been demonstrated on a large scale (305 mmol of amine). The rate differential between the reduction of tertiary and secondary amide intermediates is exemplified in a convergent synthesis of the antiretroviral medicine maraviroc. Mechanistic studies demonstrate that a residual 0.5 equivalents of carboxylic acid from the amidation step is responsible for the generation of silane reductants with augmented reactivity, which allow secondary amides, previously unreactive in zinc/phenylsilane systems, to be reduced.

Synthesis of 5,6-dihydropyrrolo[2,1-a]isoquinolines featuring an intramolecular radical-oxidative cyclization of polysubstituted pyrroles, and evaluation of their cytotoxic activity

A three-step protocol for the synthesis of 1,2,3,8,9-pentasubstituted-5,6- dihydropyrrolo[2,1-a]isoquinolines is described, using van LeuseN′s polysubstituted pyrrole construction followed by intramolecular radical-oxidative cyclization of the isoquinoline system. The cytotoxic activities of the dihydropyrroloisoquinolines were tested on six tumor cell lines. Preliminary structure-activity studies revealed the importance of the identity of the aromatic substituent at the C-2 position, particularly a phenyl, m-(amino) phenyl or m-(cyclohexylmethylpiperazinamide) phenyl substituent, for cytotoxic activity.